γ-Catenin is overexpressed in acute myeloid leukemia and promotes the stabilization and nuclear localization of β-catenin

Leukemia

Volumn 27, Issue 2, 2013, Pages 336-343

  Morgan, R G ^a   Pearn, L ^a   Liddiard, K ^a   Pumford, S L ^a   Burnett, A K ^a   Tonks, A ^a   Darley, R L ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; PLAKOGLOBIN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CONTROLLED STUDY; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; LEUKEMIA CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN TRANSPORT;

BETA CATENIN; BLOTTING, WESTERN; CELL NUCLEUS; CELLS, CULTURED; GAMMA CATENIN; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; PROMOTER REGIONS, GENETIC; PROTEIN TRANSPORT; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TCF TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 84873568995     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.221     Document Type: Article

References (52)

1. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006; 127: 469-480.
2. Staal FJ, Luis TC. Wnt signaling in hematopoiesis: crucial factors for self-renewal, proliferation, and cell fate decisions. J Cell Biochem 2010; 109: 844-849.
3. Cobas M, Wilson A, Ernst B, Mancini SJ, Macdonald HR, Kemler R et al. Beta-catenin is dispensable for hematopoiesis and lymphopoiesis. J Exp Med 2004; 199: 221-229.
4. Koch U, Wilson A, Cobas M, Kemler R, Macdonald HR, Radtke F. Simultaneous loss of beta-and gamma-catenin does not perturb hematopoiesis or lymphopoiesis. Blood 2008; 111: 160-164.
5. Jeannet G, Scheller M, Scarpellino L, Duboux S, Gardiol N, Back J et al. Long-term, multilineage hematopoiesis occurs in the combined absence of b-catenin and g-catenin. Blood 2008; 111: 142-149.
6. Kirstetter P, Anderson K, Porse BT, Jacobsen SE, Nerlov C. Activation of the canonical Wnt pathway leads to loss of hematopoietic stem cell repopulation and multilineage differentiation block. Nat Immunol 2006; 7: 1048-1056.
7. Lu D, Zhao Y, Tawatao R, Cottam HB, Sen M, Leoni LM et al. Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2004; 101: 3118-3123.
8. Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blastcrisis CML. N Engl J Med 2004; 351: 657-667.
9. Khan NI, Bradstock KF, Bendall LJ. Activation of Wnt/beta-catenin pathway mediates growth and survival in B-cell progenitor acute lymphoblastic leukaemia. Br J Haematol 2007; 138: 338-348.
10. Majeti R, Becker MW, Tian Q, Lee TL, Yan X, Liu R et al. Dysregulated gene expression networks in human acute myelogenous leukemia stem cells. Proc Natl Acad Sci USA 2009; 106: 3396-3401.
11. Chung EJ, Hwang SG, Nguyen P, Lee S, Kim JS, Kim JW et al. Regulation of leukemic cell adhesion, proliferation, and survival by beta-catenin. Blood 2002; 100: 982-990.
12. Serinsoz E, Neusch M, Busche G, Wasielewski R, Kreipe H, Bock O. Aberrant expression of beta-catenin discriminates acute myeloid leukaemia from acute lymphoblastic leukaemia. Br J Haematol 2004; 126: 313-319.
13. Simon M, Grandage VL, Linch DC, Khwaja A. Constitutive activation of the Wnt/beta-catenin signalling pathway in acute myeloid leukaemia. Oncogene 2005; 24: 2410-2420.
14. Gandillet A, Park S, Lassailly F, Griessinger E, Vargaftig J, Filby A et al. Heterogeneous sensitivity of human acute myeloid leukemia to beta-catenin downmodulation. Leukemia 2011; 25: 770-780.
15. Siapati EK, Papadaki M, Kozaou Z, Rouka E, Michali E, Savvidou I et al. Proliferation and bone marrow engraftment of AML blasts is dependent on beta-catenin signalling. Br J Haematol 2011; 152: 164-174.
16. Ysebaert L, Chicanne G, Demur C, De TF, Prade-Houdellier N, Ruidavets JB et al. Expression of beta-catenin by acute myeloid leukemia cells predicts enhanced clonogenic capacities and poor prognosis. Leukemia 2006; 20: 1211-1216.
17. Xu J, Suzuki M, Niwa Y, Hiraga J, Nagasaka T, Ito M et al. Clinical significance of nuclear non-phosphorylated beta-catenin in acute myeloid leukaemia and myelodysplastic syndrome. Br J Haematol 2008; 140: 394-401.
18. Chen CC, Gau JP, You JY, Lee KD, Yu YB, Lu CH et al. Prognostic significance of beta-catenin and topoisomerase IIalpha in de novo acute myeloid leukemia. Am J Hematol 2009; 84: 87-92.
19. Wang Y, Krivtsov AV, Sinha AU, North TE, Goessling W, Feng Z et al. The Wnt/betacatenin pathway is required for the development of leukemia stem cells in AML. Science 2010; 327: 1650-1653.
20. Yeung J, Esposito MT, Gandillet A, Zeisig BB, Griessinger E, Bonnet D et al. beta-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells. Cancer Cell 2010; 18: 606-618.
21. Muller-Tidow C, Steffen B, Cauvet T, Tickenbrock L, Ji P, Diederichs S et al. Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells. Mol Cell Biol 2004; 24: 2890-2904.
22. Zheng X, Beissert T, Kukoc-Zivojnov N, Puccetti E, Altschmied J, Strolz C et al. Gamma-catenin contributes to leukemogenesis induced by AML-associated translocation products by increasing the self-renewal of very primitive progenitor cells. Blood 2004; 103: 3535-3543.
23. Tonks A, Pearn L, Musson M, Gilkes A, Mills KI, Burnett AK et al. Transcriptional dysregulation mediated by RUNX1-RUNX1T1 in normal human progenitor cells and in acute myeloid leukaemia. Leukemia 2007; 21: 2495-2505.
24. Zhurinsky J, Shtutman M, Ben-Ze'ev A. Plakoglobin and beta-catenin: protein interactions, regulation and biological roles. J Cell Sci 2000; 113(Pt 18): 3127-3139.
25. Biechele TL, Moon RT. Assaying beta-catenin/TCF transcription with beta-catenin/TCF transcription-based reporter constructs. Methods Mol Biol 2008; 468: 99-110.
26. Hole PS, Pearn L, Tonks AJ, James PE, Burnett AK, Darley RL et al. Ras-induced reactive oxygen species promote growth factor-independent proliferation in human CD34\+ hematopoietic progenitor cells. Blood 2010; 115: 1238-1246.
27. Brown AL, Salerno DG, Sadras T, Engler GA, Kok CH, Wilkinson CR et al. The GM-CSF receptor utilizes beta-catenin and Tcf4 to specify macrophage lineage differentiation. Differentiation 2012; 83: 47-59.
28. Hwang SG, Lee HC, Trepel JB, Jeon BH. Anticancer-drug-induced apoptotic cell death in leukemia cells is associated with proteolysis of beta-catenin. Leuk Res 2002; 26: 863-871.
29. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997; 275: 1787-1790.
30. Miller JR, Moon RT. Analysis of the signaling activities of localization mutants of beta-catenin during axis specification in Xenopus. J Cell Biol 1997; 139: 229-243.
31. Solanas G, Miravet S, Casagolda D, Castano J, Raurell I, Corrionero A et al. Beta-catenin and plakoglobin N-and C-tails determine ligand specificity. J Biol Chem 2004; 279: 49849-49856.
32. Bradley RS, Cowin P, Brown AM. Expression of Wnt-1 in PC12 cells results in modulation of plakoglobin and E-cadherin and increased cellular adhesion. J Cell Biol 1993; 123: 1857-1865.
33. Kowalczyk AP, Palka HL, Luu HH, Nilles LA, Anderson JE, Wheelock MJ et al. Posttranslational regulation of plakoglobin expression. Influence of the desmosomal cadherins on plakoglobin metabolic stability. J Biol Chem 1994; 269: 31214-31223.
34. Papagerakis S, Shabana AH, Depondt J, Pibouin L, Blin-Wakkach C, Berdal A. Altered plakoglobin expression at mRNA and protein levels correlates with clinical outcome in patients with oropharynx squamous carcinomas. Hum Pathol 2004; 35: 75-85.
35. Aberle H, Bauer A, Stappert J, Kispert A, Kemler R. Beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J 1997; 16: 3797-3804.
36. Pasdar M, Li Z, Chlumecky V. Plakoglobin: kinetics of synthesis, phosphorylation, stability, and interactions with desmoglein and E-cadherin. Cell Motil Cytoskeleton 1995; 32: 258-272.
37. Simcha I, Shtutman M, Salomon D, Zhurinsky J, Sadot E, Geiger B et al. Differential nuclear translocation and transactivation potential of beta-catenin and plakoglobin. J Cell Biol 1998; 141: 1433-1448.
38. Luis TC, Ichii M, Brugman MH, Kincade P, Staal FJ. Wnt signaling strength regulates normal hematopoiesis and its deregulation is involved in leukemia development. Leukemia 2012; 26: 414-421.
39. Henderson BR, Fagotto F. The ins and outs of APC and beta-catenin nuclear transport. EMBO Rep 2002; 3: 834-839.
40. Fagotto F, Gluck U, Gumbiner BM. Nuclear localization signal-independent and importin/karyopherin-independent nuclear import of beta-catenin. Curr Biol 1998; 8: 181-190.
41. Krieghoff E, Behrens J, Mayr B. Nucleo-cytoplasmic distribution of beta-catenin is regulated by retention. J Cell Sci 2006; 119: 1453-1463.
42. Zhang N, Wei P, Gong A, Chiu WT, Lee HT, Colman H et al. FoxM1 promotes beta-catenin nuclear localization and controls Wnt target-gene expression and glioma tumorigenesis. Cancer Cell 2011; 20: 427-442.
43. Kajiguchi T, Chung EJ, Lee S, Stine A, Kiyoi H, Naoe T et al. FLT3 regulates beta-catenin tyrosine phosphorylation, nuclear localization, and transcriptional activity in acute myeloid leukemia cells. Leukemia 2007; 21: 2476-2484.
44. Kajiguchi T, Katsumi A, Tanizaki R, Kiyoi H, Naoe T. Y654 of beta-catenin is essential for FLT3/ITD-related tyrosine phosphorylation and nuclear localization of beta-catenin. Eur J Haematol 2012; 88: 314-320.
45. Maeda O, Usami N, Kondo M, Takahashi M, Goto H, Shimokata K et al. Plakoglobin (gamma-catenin) has TCF/LEF family-dependent transcriptional activity in beta-catenin-deficient cell line. Oncogene 2004; 23: 964-972.
46. Kolligs FT, Kolligs B, Hajra KM, Hu G, Tani M, Cho KR et al. Gamma-catenin is regulated by the APC tumor suppressor and its oncogenic activity is distinct from that of beta-catenin. Genes Dev 2000; 14: 1319-1331.
47. Williams BO, Barish GD, Klymkowsky MW, Varmus HE. A comparative evaluation of beta-catenin and plakoglobin signaling activity. Oncogene 2000; 19: 5720-5728.
48. Zhurinsky J, Shtutman M, Ben-Ze'ev A. Differential mechanisms of LEF/TCF familydependent transcriptional activation by beta-catenin and plakoglobin. Mol Cell Biol 2000; 20: 4238-4252.
49. Conacci-Sorrell ME, Ben-Yedidia T, Shtutman M, Feinstein E, Einat P, Ben-Ze'ev A. Nr-CAM is a target gene of the beta-catenin/LEF-1 pathway in melanoma and colon cancer and its expression enhances motility and confers tumorigenesis. Genes Dev 2002; 16: 2058-2072.
50. Fukunaga Y, Liu H, Shimizu M, Komiya S, Kawasuji M, Nagafuchi A. Defining the roles of beta-catenin and plakoglobin in cell-cell adhesion: isolation of beta-catenin/plakoglobin-deficient F9 cells. Cell Struct Funct 2005; 30: 25-34.
51. Kim YM, Ma H, Oehler VG, Gang EJ, Nguyen C, Masiello D et al. The gamma catenin/CBP complex maintains survivin transcription in beta-catenin deficient/depleted cancer cells. Curr Cancer Drug Targets 2011; 11: 213-225.
52. Reya T, Duncan AW, Ailles L, Domen J, Scherer DC, Willert K et al. A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature 2003; 423: 409-414.